Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 501 followers
Latest posts
Last updated 3 days ago
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older
3 days ago
Blujepa is the first in a new class of oral antibiotics for...
GSK, UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to collaborate on first-of-its-kind dementia research initiative
3 days ago
New collaboration aims to deepen understanding of neurodegeneration using the UK’s unique...
GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency
5 days ago
Nucala (mepolizumab) could be the first biologic with monthly dosing for patients...
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
16 days ago
Results from the study demonstrate that N6LS effectively maintained undetectable viral load...
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
16 days ago
New data at CROI 2025 show zero cases of HIV acquisition reported...
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
17 days ago
Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development...
ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025
20 days ago
Real-world and implementation data highlight effectiveness of Cabenuva and Apretude.
GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults
23 days ago
17 abstracts to evaluate unmet medical need and approaches to RSV prevention...
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
26 days ago
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
28 days ago
ANCHOR-1 and ANCHOR-2 phase III trials show improvements in nasal polyp size...
GSK plc commences share buyback programme
about 1 month ago
GSK plc announces the commencement of its share buyback programme, as announced...
GSK completes acquisition of IDRx, Inc.
about 1 month ago
GSK plc has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based...